Chemistry:SW033291

From HandWiki

SW033291 (PGDHi) is a drug which acts as a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The (R) or (+) enantiomer is more active, though much of the earlier research used the racemic mix. It increases levels of prostaglandin E2 and promotes tissue regeneration, and has shown beneficial effects for numerous potential medical applications in animal studies, including recovery from bone marrow transplant,[1][2][3] acute kidney injury,[4][5] liver damage,[6] diabetes,[7] heart failure,[8][9] cartilage regrowth,[10] sarcopenia,[11][12][13] and neurological conditions such as Alzheimer's disease and traumatic brain injury.[14]

See also

  • SW209415

References

  1. ↑ "Inhibition of 15-PGDH Protects Mice from Immune-Mediated Bone Marrow Failure". Biology of Blood and Marrow Transplantation 26 (8): 1552–1556. August 2020. doi:10.1016/j.bbmt.2020.04.010. PMID 32422251. 
  2. ↑ "15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration". JCI Insight 6 (6). March 2021. doi:10.1172/jci.insight.143658. PMID 33600377. 
  3. ↑ "Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair". Journal of Medicinal Chemistry 60 (9): 3979–4001. May 2017. doi:10.1021/acs.jmedchem.7b00271. PMID 28398755. 
  4. ↑ "Pharmacologic Blockade of 15-PGDH Protects Against Acute Renal Injury Induced by LPS in Mice". Frontiers in Physiology 11. 2020. doi:10.3389/fphys.2020.00138. PMID 32231583. 
  5. ↑ "15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury". Renal Failure 43 (1): 168–179. December 2021. doi:10.1080/0886022X.2020.1870139. PMID 33459127. 
  6. ↑ "Inhibition of 15-prostaglandin dehydrogenase attenuates acetaminophen-induced liver injury via suppression of apoptosis in liver endothelial cells". Prostaglandins, Leukotrienes, and Essential Fatty Acids 202. March 2024. doi:10.1016/j.plefa.2024.102640. PMID 39217773. 
  7. ↑ "Investigating the Mechanisms of 15-PGDH Inhibitor SW033291 in Improving Type 2 Diabetes Mellitus: Insights from Metabolomics and Transcriptomics". Metabolites 14 (9): 509. September 2024. doi:10.3390/metabo14090509. PMID 39330516. 
  8. ↑ "Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart". Circulation Research 132 (1): 10–29. January 2023. doi:10.1161/CIRCRESAHA.122.321475. PMID 36475698. 
  9. ↑ "Inhibition of 15-PGDH by SW033291 ameliorates age-related heart failure in mice". Experimental Gerontology 202. April 2025. doi:10.1016/j.exger.2025.112710. PMID 39952309. 
  10. ↑ "Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration". Science. November 2025. doi:10.1126/science.adx6649. PMID 41308124. 
  11. ↑ "Effects of SW033291 on the myogenesis of muscle-derived stem cells and muscle regeneration". Stem Cell Research & Therapy 11 (1). February 2020. doi:10.1186/s13287-020-1574-5. PMID 32085799. 
  12. ↑ "Muscle-targeted nanoparticles strengthen the effects of small-molecule inhibitors in ameliorating sarcopenia". Nanomedicine 18 (23): 1635–1649. October 2023. doi:10.2217/nnm-2023-0201. PMID 37909281. 
  13. ↑ "Biocomputational screening of natural compounds targeting 15-hydroxyprostaglandin dehydrogenase to improve skeletal muscle during aging". Molecular Diversity 28 (6): 4425–4439. December 2024. doi:10.1007/s11030-024-10825-9. PMID 38904907. 
  14. ↑ "Inhibiting 15-PGDH blocks blood-brain barrier deterioration and protects mice from Alzheimer's disease and traumatic brain injury". Proceedings of the National Academy of Sciences of the United States of America 122 (21). May 2025. doi:10.1073/pnas.2417224122. PMID 40397680. Bibcode: 2025PNAS..12217224K. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:SW033291&oldid=4245605"